Prescribe Right
Prescribe Right
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us
Pipeline News and Updates
Picture

EVIDENCE BASED FORMULARY DECISION SUPPORT

10/14/2020

 
According to a recent survey, 75% of hospitals utilize their internal pharmacy staff to prepare and create drug reviews for P&T. Gathering the supporting data about these drugs requires searching multiple sources: clinical journals, FDA announcements, medical conference summaries, presentations, industry newsletters, and pharmaceutical company announcements. This process takes clinical pharmacists away from participating at the point of care, between 10 and 20 hours per month! 
 
Yet, survey respondents either wait until after a drug received FDA approval to begin evaluating the drugs' appropriateness for their formulary; only review high cost drugs prior to FDA approval; or sometimes review a practice-changing drug prior to approval. 
 
One could postulate that this practice of post FDA approval review aligns with point-of-care availability of newly approved drug information in knowledgebases feeding point-of-care patient record software. 
 
However, pre-FDA efficient drug approval review is possible by re-purposing staff time toward analysis rather than data-gathering. The following benefits accrue:
  1. patient populations that benefit from breakthrough technologies receive new treatments sooner.
  2. more time to plan for efficient and economical adoption of practice changing treatments.
  3. earlier prescriber education materials.
  4. more time to determine how to mitigate the impact of extremely expensive therapies. ​
A single source of critical, unbiased, comprehensive information about the pharmaceutical pipeline is available to prospectively prepare the P&T evaluation of new drugs. The Pharmaceutical Pipeline Tracker was created to fulfill the need. The web-delivered easily searchable knowledgebase includes information to create P&T drug reviews: generic names, brand names (if known), indication, therapeutic area, mechanism of action, route, PDUFA Date (if established), FDA status (Phase I, II, III, or approved) efficacy and safety. 
 
Evidence based decision support within the Pharmaceutical Pipeline Tracker includes a summary of efficacy and safety along with the latest news and analysis from clinical journals, FDA announcements, medical conference summaries, presentations, industry newsletters, and pharmaceutical company announcements. As a bonus, there is additional evidence via links to published studies via PubMed. 
 
It’s time to re-think how you prepare for P&T new drug reviews.
Click here for access to The Pharmaceutical Pipeline Tracker for only $339! Utilize all of the functions and access all of the evidence based intelligence about 888 investigational drugs in the pipelines of over 400 pharmaceutical companies. Access includes links to 1546 late stage clinical trial results. Limited time offer. No automatic renewal. 

Comments are closed.
    Stay informed, subscribe to the 
    ​
    Prescribe Right Pharmaceutical Pipeline Tracker
    Latest Tweets from Prescribe Right

    Archives

    January 2023
    December 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    September 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    August 2015

    RSS Feed

Services

Pharmaceutical Pipeline Tracker​
Consulting

Company

About
Blog
Tweets

Support

Contact
© COPYRIGHT 2015. ALL RIGHTS RESERVED.